Emergent BioSolutions | EBS - Operating Profit


Emergent BioSolutions reported $-218M in Operating Profit for its fiscal quarter ending in June of 2023.





Operating Profit Change Date
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
ALKERMES USD -10.95M 100.03M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amarin USD -2.26M 564K Dec/2025
ANI Pharmaceuticals USD 29.13M 6.3M Dec/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Emergent BioSolutions USD -218M 69.9M Jun/2023
Exelixis USD 235.91M 20.45M Dec/2025
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
Heron Therapeutics USD 38K 3.83M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
Lonza CHF 673M 243M Jun/2025
Merck USD 6.24B 318M Dec/2025
Moderna USD -857M 597M Dec/2025
Myriad Genetics USD -3M 20.3M Dec/2025
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Pacira USD 3.19M 9.96M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
United Therapeutics USD -14.6M 403.9M Dec/2025
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024
Xoma USD -15.64M 5.56M Sep/2024